Identifying FLT3 mutations

Data selected from a prospective analysis (November 2016 through January 2019) of 395 eligible patients with suspected AML across 14 clinical sites aimed to provide cytogenetic and mutational data within 7 days. Patients were assigned treatment based on cytogenetic and molecular results. Eligible patients had been untreated and were ≥60 years old and assigned to a substudy based on the dominant clone determined through testing. Overall survival results data from patients given therapy based on AML mutation (n=224) vs standard therapy (n=103) were included. 30-day mortality data from all 395 eligible patients were reviewed and analyzed. Median follow-up for OS was 7.1 months (range: 0–24.8 months).

This study does not distinguish the benefit of treatment compared with clinical trial enrollment. The treatment arms within this trial are designed with specific considerations of newer agents with therapeutic relevance and will continue to adapt to changes in the AML treatment landscape. For more details regarding study design and limitations, please see the full study article.

Waiting up to 7 days for biomarker results did not adversely impact overall survival¹³